Index RUT P/E - EPS (ttm) -2.18 Insider Own 16.54% Shs Outstand 74.35M Perf Week 4.74%
Market Cap 1.60B Forward P/E - EPS next Y -2.62 Insider Trans -0.86% Shs Float 69.01M Perf Month 3.19%
Income -168.09M PEG - EPS next Q -0.62 Inst Own 93.81% Short Float 14.66% Perf Quarter 2.24%
Sales 0.00M P/S - EPS this Y -19.71% Inst Trans 4.42% Short Ratio 11.04 Perf Half Y 149.52%
Book/sh 6.63 P/B 3.17 EPS next Y -5.28% ROA -34.31% Short Interest 10.12M Perf Year 87.42%
Cash/sh 6.92 P/C 3.04 EPS next 5Y 19.93% ROE -37.34% 52W Range 7.41 - 24.17 Perf YTD 46.11%
Dividend Est. - P/FCF - EPS past 5Y -3.94% ROI -32.28% 52W High -13.07% Beta 0.94
Dividend TTM - Quick Ratio 16.67 Sales past 5Y 0.00% Gross Margin - 52W Low 183.54% ATR (14) 0.94
Dividend Ex-Date - Current Ratio 16.67 EPS Y/Y TTM -6.72% Oper. Margin 0.00% RSI (14) 60.18 Volatility 4.17% 4.52%
Employees 142 Debt/Eq 0.03 Sales Y/Y TTM - Profit Margin - Recom 1.21 Target Price 30.25
Option/Short Yes / Yes LT Debt/Eq 0.03 EPS Q/Q -18.51% Payout - Rel Volume 0.84 Prev Close 20.63
Sales Surprise - EPS Surprise -7.84% Sales Q/Q - Earnings May 02 AMC Avg Volume 916.15K Price 21.01
SMA20 8.53% SMA50 1.81% SMA200 49.41% Trades
Volume 770,598 Change 1.84%
Date
Action
Analyst
Rating Change
Price Target Change
Dec-22-23 Initiated Mizuho
Buy
$26
Aug-11-23 Initiated BofA Securities
Buy
$31
Jul-27-23 Initiated Scotiabank
Sector Perform
$10.50
May-17-23 Initiated BTIG Research
Buy
$31
Jan-31-23 Initiated Stifel
Buy
$25
Jul-12-22 Initiated Cantor Fitzgerald
Overweight
$30
Feb-15-22 Initiated Jefferies
Buy
$35
May-05-21 Resumed Credit Suisse
Outperform
$42
Apr-26-21 Resumed Credit Suisse
Outperform
$42
Dec-07-20 Reiterated H.C. Wainwright
Buy
$40 → $45
Dec-03-20 Initiated Stifel
Buy
$45
Nov-05-20 Downgrade Piper Sandler
Overweight → Neutral
Jul-07-20 Initiated Credit Suisse
Outperform
$27
May-05-20 Initiated Barclays
Overweight
$24
Jul-18-19 Initiated Deutsche Bank
Buy
$28
Nov-09-18 Initiated Piper Jaffray
Overweight
Aug-01-18 Initiated H.C. Wainwright
Buy
$31
Oct-13-16 Resumed Leerink Partners
Outperform
$15
Jan-22-16 Initiated JMP Securities
Mkt Outperform
Dec-30-15 Initiated Oppenheimer
Outperform
$16
Show Previous Ratings
Today 10:14AM
May-03-24 07:30AM
04:03AM
May-02-24 08:58PM
04:48PM
(Associated Press Finance)
04:05PM
Loading…
04:05PM
Apr-25-24 07:30AM
Apr-22-24 07:30AM
Apr-10-24 07:30AM
Apr-05-24 07:30AM
Mar-06-24 07:30AM
Mar-01-24 05:00PM
Feb-28-24 09:56AM
06:56AM
(Thomson Reuters StreetEvents)
Feb-27-24 04:44PM
04:10PM
Loading…
04:10PM
(Associated Press Finance)
04:01PM
Feb-26-24 07:30AM
Feb-22-24 07:30AM
Feb-20-24 07:30AM
Feb-02-24 07:30AM
Feb-01-24 03:01PM
Jan-30-24 04:07PM
(Investor's Business Daily) +12.10%
07:00AM
Jan-24-24 04:22PM
(Investor's Business Daily) +46.13%
01:16PM
07:00AM
Dec-08-23 07:30AM
Nov-28-23 07:30AM
Nov-05-23 03:44PM
06:46PM
Loading…
Nov-02-23 06:46PM
04:36PM
(Associated Press Finance)
04:01PM
07:30AM
Oct-30-23 07:30AM
Oct-26-23 04:05PM
Oct-19-23 07:30AM
Oct-17-23 04:05PM
Oct-09-23 02:03AM
Oct-04-23 12:00PM
07:30AM
Sep-28-23 07:30AM
Sep-19-23 07:30AM
Aug-14-23 07:30AM
Aug-03-23 04:38PM
(Associated Press Finance)
04:05PM
Jul-27-23 07:30AM
Jul-11-23 09:35AM
Jun-14-23 07:00AM
Jun-13-23 04:01PM
Jun-11-23 03:45AM
Jun-05-23 08:02PM
May-30-23 07:30AM
May-23-23 07:30AM
May-13-23 11:51AM
May-11-23 09:35AM
(Thomson Reuters StreetEvents) +8.30%
May-10-23 04:17PM
04:03PM
May-09-23 07:30AM
May-03-23 07:30AM
May-01-23 02:07PM
Apr-18-23 07:30AM
Apr-17-23 07:30AM
Mar-14-23 05:32PM
Mar-01-23 07:30AM
Feb-26-23 06:47AM
Feb-24-23 12:52PM
(Thomson Reuters StreetEvents)
Feb-23-23 04:03PM
Feb-16-23 07:30AM
Feb-12-23 07:14AM
Feb-09-23 07:30AM
Feb-07-23 07:30AM
Jan-31-23 05:43PM
Jan-24-23 07:30AM
Jan-06-23 07:21AM
Dec-12-22 11:34AM
Dec-10-22 10:30AM
Dec-01-22 09:55AM
07:30AM
Nov-22-22 09:40AM
07:30AM
Nov-14-22 09:55AM
Nov-03-22 09:40AM
09:00AM
07:30AM
07:00AM
Nov-02-22 07:30AM
Oct-27-22 07:30AM
Oct-26-22 01:13PM
07:30AM
Oct-19-22 02:23PM
(Investor's Business Daily)
Sep-01-22 07:30AM
Aug-11-22 03:06PM
Aug-08-22 02:51PM
(Investor's Business Daily)
Aug-03-22 04:03PM
Aug-02-22 07:30AM
Jul-27-22 07:30AM
Jul-17-22 10:19AM
Jul-13-22 03:05PM
Jun-30-22 02:02PM
(Investor's Business Daily)
Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
DALE STEPHEN Chief Medical Officer Jan 30 '24 Sale 21.55 4,825 103,980 38,817 Jan 31 05:30 PM DALE STEPHEN Chief Medical Officer Jan 29 '24 Sale 17.80 7,158 127,416 43,642 Jan 31 05:30 PM DOYLE THOMAS JAMES SVP, Finance & Accounting Jan 29 '24 Sale 17.80 2,318 41,262 48,093 Jan 31 05:30 PM Bair Teresa Brophy Chief Legal Officer Jan 29 '24 Sale 17.80 2,053 36,544 68,979 Jan 31 05:30 PM FORD KATHLEEN Chief Operating Officer Jan 29 '24 Sale 17.80 1,496 26,630 21,602 Jan 31 05:30 PM WILSON TROY EDWARD President and CEO Jan 24 '24 Option Exercise 6.05 91,052 550,594 84,666 Jan 26 05:10 PM WILSON TROY EDWARD President and CEO Jan 24 '24 Sale 20.23 91,052 1,841,982 559 Jan 26 05:10 PM Malley Thomas Director Jun 16 '23 Buy 11.50 50,000 575,000 139,557 Jun 21 04:29 PM
Index - P/E 14.36 EPS (ttm) 0.32 Insider Own 28.05% Shs Outstand 47.65M Perf Week -7.97%
Market Cap 222.87M Forward P/E 18.99 EPS next Y 0.24 Insider Trans -0.82% Shs Float 34.71M Perf Month -18.37%
Income 15.38M PEG - EPS next Q -0.05 Inst Own 54.93% Short Float 9.58% Perf Quarter -5.33%
Sales 226.63M P/S 0.98 EPS this Y -45.93% Inst Trans -2.11% Short Ratio 5.71 Perf Half Y 85.54%
Book/sh 1.06 P/B 4.37 EPS next Y 0.00% ROA 7.49% Short Interest 3.33M Perf Year 77.01%
Cash/sh 2.22 P/C 2.08 EPS next 5Y - ROE 40.02% 52W Range 2.13 - 7.73 Perf YTD 6.70%
Dividend Est. - P/FCF 6.28 EPS past 5Y - ROI 13.80% 52W High -40.23% Beta 1.09
Dividend TTM - Quick Ratio 1.38 Sales past 5Y -0.59% Gross Margin 73.44% 52W Low 116.90% ATR (14) 0.33
Dividend Ex-Date - Current Ratio 1.46 EPS Y/Y TTM 202.04% Oper. Margin 11.74% RSI (14) 35.68 Volatility 7.17% 6.02%
Employees 185 Debt/Eq 2.17 Sales Y/Y TTM -3.59% Profit Margin 6.78% Recom 3.00 Target Price 4.33
Option/Short Yes / Yes LT Debt/Eq 1.19 EPS Q/Q -436.36% Payout 0.00% Rel Volume 1.00 Prev Close 4.86
Sales Surprise -10.70% EPS Surprise 53.85% Sales Q/Q -17.07% Earnings May 02 AMC Avg Volume 582.11K Price 4.62
SMA20 -10.51% SMA50 -13.97% SMA200 9.63% Trades
Volume 583,454 Change -4.94%
Date
Action
Analyst
Rating Change
Price Target Change
Sep-28-21 Upgrade Citigroup
Neutral → Buy
$11
Jun-25-20 Resumed BofA/Merrill
Underperform
$9
Oct-08-19 Downgrade Goldman
Neutral → Sell
$24 → $8
May-10-19 Downgrade Citigroup
Buy → Neutral
$24
May-10-19 Downgrade Cantor Fitzgerald
Overweight → Neutral
$57 → $20
Jan-17-19 Initiated Leerink Partners
Mkt Perform
$21
Jan-03-19 Downgrade Guggenheim
Buy → Neutral
Nov-19-18 Upgrade Goldman
Sell → Neutral
Nov-02-18 Downgrade JP Morgan
Neutral → Underweight
Nov-02-18 Downgrade BofA/Merrill
Buy → Underperform
Oct-01-18 Initiated Cantor Fitzgerald
Overweight
$75
Sep-17-18 Initiated Goldman
Sell
$42
May-11-18 Reiterated Stifel
Buy
$95 → $87
Nov-10-17 Reiterated RBC Capital Mkts
Sector Perform
$92 → $108
Nov-10-17 Reiterated Citigroup
Buy
$156 → $164
Oct-02-17 Reiterated Stifel
Buy
$110 → $130
Sep-11-17 Reiterated Credit Suisse
Outperform
$118 → $136
Jul-10-17 Resumed Leerink Partners
Outperform
$115
Jun-06-17 Reiterated RBC Capital Mkts
Sector Perform
$60 → $88
May-25-17 Reiterated RBC Capital Mkts
Sector Perform
$40 → $60
Show Previous Ratings
May-03-24 01:09PM
11:31AM
04:02AM
May-02-24 09:55PM
06:05PM
05:48PM
Loading…
05:48PM
05:12PM
(Associated Press Finance)
04:05PM
Apr-26-24 11:40AM
Apr-25-24 10:02AM
Apr-18-24 04:15PM
Apr-11-24 06:00PM
Apr-03-24 05:30PM
Mar-22-24 09:25AM
Mar-20-24 08:30AM
08:29AM
Loading…
Mar-02-24 08:29AM
Mar-01-24 09:55AM
(Thomson Reuters StreetEvents) -5.31%
09:40AM
09:39AM
Feb-29-24 04:41PM
04:40PM
(Associated Press Finance)
04:05PM
Feb-27-24 06:30PM
11:51AM
Feb-22-24 04:10PM
Feb-15-24 04:10PM
Feb-13-24 08:30AM
Jan-31-24 12:58PM
Jan-11-24 04:07PM
Jan-06-24 11:02AM
08:30AM
Loading…
Dec-11-23 08:30AM
Nov-20-23 11:47AM
Nov-06-23 05:15PM
Nov-03-23 12:16PM
09:34AM
(Thomson Reuters StreetEvents)
09:31AM
Nov-02-23 07:42PM
04:47PM
(Associated Press Finance)
04:05PM
Oct-19-23 04:14PM
Oct-14-23 12:30PM
Oct-04-23 05:30PM
Sep-22-23 07:57AM
Sep-21-23 04:10PM
Aug-31-23 04:07PM
Aug-08-23 08:30AM
Aug-04-23 12:36PM
09:23AM
(Thomson Reuters StreetEvents)
Aug-03-23 05:17PM
04:05PM
Jul-20-23 04:15PM
Jun-13-23 09:30AM
Jun-06-23 05:03PM
Jun-04-23 09:00AM
May-28-23 10:06AM
May-22-23 11:07AM
May-05-23 05:15PM
12:45PM
09:44AM
(Thomson Reuters StreetEvents)
May-04-23 05:32PM
04:04PM
Apr-20-23 04:15PM
Apr-17-23 06:49AM
Apr-11-23 05:15PM
Mar-14-23 08:30AM
Mar-06-23 09:48AM
Mar-03-23 05:15PM
02:20PM
06:22AM
(Thomson Reuters StreetEvents)
Mar-02-23 04:05PM
Feb-28-23 04:15PM
Feb-19-23 02:05PM
Feb-16-23 04:31PM
Feb-07-23 05:30PM
Feb-01-23 08:30AM
Jan-25-23 06:19AM
Jan-12-23 04:15PM
Jan-11-23 05:30PM
Jan-09-23 08:55AM
Dec-20-22 08:31AM
Dec-15-22 03:39PM
Dec-07-22 06:03PM
Dec-05-22 05:30PM
Dec-01-22 08:36AM
Nov-28-22 09:55AM
Nov-22-22 09:15AM
08:50AM
Nov-21-22 05:25PM
Nov-17-22 09:40AM
Nov-14-22 10:10AM
09:50AM
Nov-11-22 10:20AM
Nov-09-22 10:43AM
06:02AM
Nov-07-22 01:02PM
(Simply Wall St.) +15.50%
Nov-04-22 12:29PM
12:20PM
12:18PM
11:18AM
Nov-03-22 06:45PM
Puma Biotechnology, Inc. is a biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. It focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The company was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
AUERBACH ALAN H President and CEO Jan 03 '24 Sale 4.49 41,396 185,698 6,936,947 Jan 05 06:56 PM NOUGUES MAXIMO F Chief Financial Officer Jan 03 '24 Sale 4.49 15,682 70,348 128,666 Jan 05 06:49 PM Ludwig Jeffrey Jerome Chief Commercial Officer Jan 03 '24 Sale 4.49 12,956 58,119 99,970 Jan 05 07:00 PM HUNT DOUGLAS M See Remarks Jan 03 '24 Sale 4.49 8,358 37,493 103,319 Jan 05 06:42 PM Wong Alvin F Chief Scientific Officer Jan 03 '24 Sale 4.49 7,733 34,689 98,214 Jan 05 07:03 PM Wong Alvin F Chief Scientific Officer Dec 04 '23 Sale 3.76 280 1,053 97,934 Jan 10 04:41 PM MILLER MICHAEL PATRICK Director Nov 07 '23 Sale 2.83 25,000 70,802 43,358 Nov 09 04:19 PM AUERBACH ALAN H President and CEO Jul 03 '23 Sale 3.31 60,698 200,983 6,978,343 Jul 06 07:03 PM NOUGUES MAXIMO F Chief Financial Officer Jul 03 '23 Sale 3.31 14,680 48,608 144,348 Jul 06 07:12 PM Ludwig Jeffrey Jerome Chief Commercial Officer Jul 03 '23 Sale 3.31 12,103 40,075 112,926 Jul 06 07:08 PM HUNT DOUGLAS M See Remarks Jul 03 '23 Sale 3.31 7,809 25,857 111,677 Jul 06 07:06 PM Wong Alvin F Chief Scientific Officer Jul 03 '23 Sale 3.31 6,938 22,973 105,947 Jul 06 07:16 PM Senderowicz Adrian Director Jun 13 '23 Sale 3.45 27,000 93,280 0 Jun 15 09:03 PM WILSON TROY EDWARD Director Jun 13 '23 Sale 3.45 27,000 93,269 350 Jun 15 09:14 PM MOYES JAY M Director Jun 13 '23 Sale 3.45 22,000 75,970 16,322 Jun 15 09:10 PM MILLER MICHAEL PATRICK Director Jun 13 '23 Sale 3.45 13,500 46,630 41,358 Jun 15 08:28 PM Dorval Allison Director Jun 13 '23 Sale 3.45 10,000 34,500 17,000 Jun 15 09:01 PM Stuglik Brian M Director Jun 13 '23 Sale 3.46 9,900 34,252 31,958 Jun 15 09:06 PM Wong Alvin F Chief Scientific Officer Jun 02 '23 Sale 3.45 269 928 112,885 Jun 06 04:36 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
